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Abstract: Background Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal anti-
bodies have significantly improved survival in advanced melanoma. Biomarkers are urgently needed as
a majority of patients do not respond, despite treatment-related toxicities. We analysed pre-treatment
18F-fluorodeoxyglucose positron emission tomography/computerised tomography (FDG PET/CT) pa-
rameters to assess its correlation with patient outcome. Methods This retrospective study evaluated
pre-treatment FDG PET/CT scans in a discovery cohort of patients with advanced melanoma treated
with ipilimumab or anti-PD1. Pre-treatment scans were assessed for maximum tumoral standardised up-
take value (SUVmax), metabolic tumour volume (MTV) and spleen to liver ratio (SLR). Progression-free
survival (PFS) and overall survival (OS) were characterised and modelled using univariable and multi-
variable analyses. Correlation of SLR and OS was validated in an independent cohort. Blood parameters
and stored sera of patients from the discovery cohort was analysed to investigate biological correlates with
SLR. Results Of the 90 evaluable patients in the discovery cohort: 50 received ipilimumab monotherapy,
20 received anti-PD1 monotherapy, and 20 patients received ipilimumab followed by anti-PD1 upon dis-
ease progression. High SLR > 1.1 was associated with poor PFS (median 1 vs 3 months; HR 3.14, p =
0.008) for patients treated with ipilimumab. High SLR was associated with poor OS after ipilimumab
(median 1 vs 21 months; HR 5.83, p = 0.0001); as well as poor OS after first line immunotherapy of either
ipilimumab or anti-PD1 (median 1 vs 14 months; HR 3.92, p = 0.003). The association of high SLR and
poor OS after ipilimumab was validated in an independent cohort of 110 patients (median 2.3 months
versus 11.9 months, HR 3.74). SLR was associated with poor OS in a multi-variable model independent
of stage, LDH, absolute lymphocyte count and MTV. Conclusions Pre-treatment Spleen to liver ratio
(SLR) > 1.1 was associated with poor outcome after ipilimumab in advanced melanoma. This parameter
warrants prospective evaluation.
DOI: https://doi.org/10.1186/s40644-020-00313-2






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Wong, Annie; Callahan, Jason; Keyaerts, Marleen; Neyns, Bart; Mangana, Johanna; Aberle, Susanne;
Herschtal, Alan; Fullerton, Sonia; Milne, Donna; Iravani, Amir; McArthur, Grant A; Hicks, Rodney J
(2020). 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in
patients with metastatic melanoma. Cancer Imaging, 20(1):36.
DOI: https://doi.org/10.1186/s40644-020-00313-2
2
RESEARCH ARTICLE Open Access
18F-FDG PET/CT based spleen to liver ratio
associates with clinical outcome to
ipilimumab in patients with metastatic
melanoma
Annie Wong1,2*, Jason Callahan3, Marleen Keyaerts4,5, Bart Neyns6, Johanna Mangana7, Susanne Aberle8,
Alan Herschtal9, Sonia Fullerton10, Donna Milne11, Amir Iravani3, Grant A. McArthur1,2† and Rodney J. Hicks1,2,3†
Abstract
Background: Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal antibodies have
significantly improved survival in advanced melanoma. Biomarkers are urgently needed as a majority of patients do not
respond, despite treatment-related toxicities. We analysed pre-treatment 18F-fluorodeoxyglucose positron emission
tomography/computerised tomography (FDG PET/CT) parameters to assess its correlation with patient outcome.
Methods: This retrospective study evaluated pre-treatment FDG PET/CT scans in a discovery cohort of patients with
advanced melanoma treated with ipilimumab or anti-PD1. Pre-treatment scans were assessed for maximum tumoral
standardised uptake value (SUVmax), metabolic tumour volume (MTV) and spleen to liver ratio (SLR). Progression-free
survival (PFS) and overall survival (OS) were characterised and modelled using univariable and multivariable analyses.
Correlation of SLR and OS was validated in an independent cohort. Blood parameters and stored sera of patients from
the discovery cohort was analysed to investigate biological correlates with SLR.
Results: Of the 90 evaluable patients in the discovery cohort: 50 received ipilimumab monotherapy, 20 received anti-PD1
monotherapy, and 20 patients received ipilimumab followed by anti-PD1 upon disease progression. High SLR > 1.1 was
associated with poor PFS (median 1 vs 3months; HR 3.14, p= 0.008) for patients treated with ipilimumab. High SLR was
associated with poor OS after ipilimumab (median 1 vs 21months; HR 5.83, p= 0.0001); as well as poor OS after first line
immunotherapy of either ipilimumab or anti-PD1 (median 1 vs 14months; HR 3.92, p= 0.003). The association of high SLR
and poor OS after ipilimumab was validated in an independent cohort of 110 patients (median 2.3months versus 11.9
months, HR 3.74). SLR was associated with poor OS in a multi-variable model independent of stage, LDH, absolute
lymphocyte count and MTV.
Conclusions: Pre-treatment Spleen to liver ratio (SLR) > 1.1 was associated with poor outcome after ipilimumab in advanced
melanoma. This parameter warrants prospective evaluation.
Keywords: Melanoma, Immune checkpoint blockade, Biomarker, Positron emission tomography, Spleen to liver ratio
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Annie.Wong@petermac.org
†Grant A. McArthur and Rodney J. Hicks contributed equally to this work.
1Research Division, Peter MacCallum Cancer Centre, 305 Grattan St,
Melbourne, VIC 3000, Australia
2Sir Peter MacCallum Department of Oncology, University of Melbourne,
Melbourne, VIC 3010, Australia
Full list of author information is available at the end of the article
Wong et al. Cancer Imaging           (2020) 20:36 
https://doi.org/10.1186/s40644-020-00313-2
Background
The advent of immune checkpoint blockade has resulted in
unprecedented improvements in survival for patients with
metastatic melanoma. However, response rates of approxi-
mately 10 and 40% respectively for anti-CTLA4 (ipilimu-
mab) [1, 2] and anti-PD1 monoclonal antibodies [3–5],
indicate that the majority of patients do not respond. In
2015, the combination ipilimumab and nivolumab demon-
strated improved response rates and progression-free sur-
vival compared to single agent ipilimumab [6, 7]. However,
this combination resulted in significantly higher treatment-
related toxicity than monotherapy (55% vs 16–27% patients
experienced common toxicity criteria for adverse events
grade 3 and 4 toxicities respectively). Even then, 42% of pa-
tients still failed to achieve an objective response. Hence,
biomarkers that can predict clinical outcomes are urgently
needed.
There are numerous candidate predictive biomarkers
including expression of tumoral PDL1 [8, 9] and tumoral
mutational load [10], but these have not entered clinical
practice due to their inability to clearly prospectively
identify responders from non-responders. It is now
recognised that a combination of different biomarkers
may be needed to predict response given the complexity
of the immune interaction with tumour [11]. Blank et al.
suggested a ‘cancer immunogram’ wherein a combin-
ation of biomarkers such as tumoral mutational load,
presence of T-cell checkpoints, soluble cytokines, meta-
bolic factors and host immune factors should be consid-
ered. Here we explore how existing non-invasive functional
imaging might provide a readily translatable source of novel
biomarkers, given the current increase of 18F-fluorodeoxy-
glucose positron emission tomography/computerised tom-
ography (FDG PET/CT) in the surveillance of high-risk
melanoma [12] or at suspected relapse [13].
18F-fluoro-deoxy-glucose positron emission tomog-
raphy (FDG PET) has long been the preferred functional
imaging technique in melanoma in our facility [14]. Our
identification of malignancy is largely qualitative based
on a combination of PET and CT appearances [15] since
the use of the semi-quantitative measure of uptake in-
tensity termed the standardised uptake value (SUV) can
have limitations with regards to cancer evaluation due to
the large number of technical factors that can influence
its measurement [16]. Nevertheless, the measurement of
SUVmax has been shown to have some prognostic sig-
nificance in a number of malignancies, including melan-
oma [17]. Metabolic tumour volume (MTV) is a
measure of metabolically active disease and, reflecting
the burden of disease, might be more likely to correlate
with clinical outcome.
In addition to studying PET-derived parameters of the
tumour, there may be merit in examining the patients’
tissues, such as the spleen or draining lymph nodes, as a
way of characterising immune status. The SUV of nor-
mal organs, particularly the liver and spleen, generally
have a rather narrow range [18, 19]. For example, the
liver normally exhibits homogenous uptake of FDG
(normal SUVmax of liver in men range from 2.3–5.0
and 2.3–3.8 in women) [20], unless there is obvious dis-
ease infiltration or sarcoidosis. The spleen is the largest
lymphoid organ in the body, and normally has less FDG
uptake compared to the liver (normal SUVmax of spleen
in men range from 1.6–4.1 and 1.6–3.2 in women), with
an expected Spleen to Liver Ratio (SLR) of approxi-
mately 0.9 [20–22]. High splenic uptake or high SLR has
been observed in patients with infections as well as pa-
tients with cancers associated with an inflammatory
state, such as Hodgkin’s disease [23] or cholangiocarci-
noma [21, 22, 24]. There have also been reports of im-
mune activation as a result of interferon alpha 2b or
anti-CTLA4 [25]. Hence PET evaluation of immune or-
gans of patients receiving immunotherapy may be of
clinical value. In this article, we analysed baseline FDG
PET/CT performed on patients prior to immunotherapy
and its correlation with clinical outcome to identify
novel PET imaging biomarkers.
Methods
Patients
All patients with unresectable stage III or stage IV melan-
oma (with progressive disease) who received monotherapy
with ipilimumab or anti-PD1 (either pembrolizumab or
nivolumab) and had completed a pre-treatment FDG PET
scan at Peter MacCallum Cancer Centre (PMCC) between
1st July 2010 and 30thJune 2015 were included. Prior treat-
ment with BRAF targeted therapies was permissible but
patients treated with BRAF/MEK inhibitors post progres-
sion on ipilimumab or anti-PD1 were excluded. Ipilimu-
mab was given at 3 mg/kg intravenously every 3 weeks for
four doses. Pembrolizumab was given at 2 mg/kg intraven-
ously every 3 weeks, and nivolumab was given at 3mg/kg
intravenously every 2 weeks until disease progression. Pa-
tients received anti-PD1 either as monotherapy or upon
progression after ipilimumab treatment (i.e. concurrent
ipilimumab and nivolumab treatment was not included).
Medical records were retrospectively reviewed for patient
demographics, disease characteristics, blood parameters,
treatment and clinical outcome. Treatment response was
determined by local treating oncologist based on available
clinical and imaging data.
We then sought to validate the association between
SLR > 1.1 and OS in an additional cohort. Eligible patients
treated at UZ Brussel, Brussels and University Hospital
Zurich, Zurich were combined into a single validation co-
hort. Patients treated with at least one dose of ipilimumab
were included and patient demographics, date of death or
last contact were recorded. Pre-treatment PET scans were
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assessed for SLR by the local nuclear medicine expert. The
final statistical analysis was performed at PMCC. This study
was approved by human research ethics committees and
the requirement for informed consent was waived at the
PMCC, the UZ Brussel, and the University Hospital Zurich.
FDG-PET/CT imaging analysis
Pre-treatment PET scans were performed within 6weeks be-
fore commencing ipilimumab or anti-PD1. At PMCC, the
analysis was performed by using MIM software, which pro-
vided an automated volume-of-interest analysis on the basis
of user-defined search regions. Parameters evaluated in-
cluded the SUVmax for all tumour lesions, MTV and SLR.
Metabolic tumour volume (mL), was calculated by multiply-
ing the number of abnormal voxels identified within the vol-
ume of interest by the known voxel volume by adapting the
PERCIST recommendations for contouring FDG-avid dis-
ease [26]. All FDG-avid disease was contoured using an SUV
threshold, which was applied to the whole body. The SUV
threshold used was 1.5 times the mean SUV of the liver plus
2 standard deviations. The SLR is calculated by placing 2 cm
spherical volumes of interest in the liver and spleen (Fig. 1).
The ratio of the SUVmean of the spleen to the SUVmean of
the liver is then calculated. A SLR of greater than 1.1 was
considered abnormal. If the patient had metastases in either
the liver or the spleen, the volumes of interest would be
placed in the adjacent normal organ tissue to avoid areas of
metastases. The validation sites were only required to evalu-
ate the SLR. Detailed PET acquisition methodology is in-
cluded in supplementary materials (S1).
Statistical analyses
FDG PET/CT parameters (tumoral SUVmax, MTV and
SLR) were tested for association with PFS and OS after
ipilimumab and anti-PD1, with treatment line and
metastasis substage considered as confounding variables
[27, 28]. PFS and OS were tested for association with
PET/CT parameters using Cox proportional hazards re-
gression. The median tumoral SUVmax and MTV were
calculated using all pre-treatment scans in the discovery
cohort (n = 110). These median values were used to
dichotomize the cohort to compare high tumoral SUV-
max versus low tumoral SUVmax, as well as high MTV
versus low MTV. Tumoral SUVmax and MTV were also
analysed as continuous variables. The SLR normally var-
ies within a tight range of 0.9–1.0; consequently SLR >
1.1 was considered abnormally high and used as the
threshold for survival analyses. PFS was assessed and
modelled separately for ipilimumab and anti-PD1 and
was measured from the start of immunotherapy to
the date of progression or death; patients were cen-
sored at date of last contact. Progression was assessed
either clinically (if patient had died or was too unwell
for imaging), or clinical imaging with either PET, CT
or MRI. OS was assessed and modelled separately for
a) ipilimumab, b) anti-PD1 and c) first line immuno-
therapy (either ipilimumab or anti-PD1, whichever
was received first). OS was measured from start of
treatment until death or censored at date of last con-
tact. Other analyses for survival after first line im-
munotherapy considered LDH, metastasis substage
(AJCC 7th Edition) [27], MTV, ALC and SLR. Statis-
tical analyses were performed using the base package
and the survival package (R version 3.4.2). Kaplan-
Meier survival curves were used to present survival
outcome for SUV and MTV as dichotomized at the
median for the treatment cohort, or at the abnormal
threshold of SLR > 1.1. The additional cohorts (UZB
and UHZ) were used to validate the association of
SLR with OS after ipilimumab.
Fig. 1 Spleen to Liver Ratio (SLR) on positron emission tomography. Example of normal splenic FDG tracer uptake (left) compared to abnormally
high tracer uptake within the spleen (right). The SUV is calculated by placing 2 cm spherical volumes of interest in the liver and spleen
respectively (as depicted by red circles). The spleen to liver ratio (SLR) is calculated by dividing the SUVmean of the spleen by the SUVmean of
the liver. SLR > 1.1 is considered abnormally high
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Biological analyses on discovery cohort
To explore the relationship between SLR and inflamma-
tory and haematological parameters, a multi-variable lin-
ear regression model was built to explore predictor
variables including: neutrophil: lymphocyte ratio,
haemoglobin, LDH, ALC × 109, albumin, lymphocyte:
monocyte ratio and patient performance status (Supple-
mentary materials S2).
A subset of patients in the discovery cohort were also en-
rolled in a separate biomarker study where their sera were
stored at multiple time points. Pre-treatment samples were
taken at baseline, prior to treatment at week 3 and prior to
week 6. We sought to evaluate baseline and dynamic changes
in the cytokine profile of patients with high SLR compared to
those with normal SLR (Supplementary materials S3). Stored
serum samples were tested using the BD Cytometric Bead
Array Enhanced Sensitivity kit for IL1β, IL2, IL4, IL6, IL10,
IL12p70, IL17A, TNF, IFNγ as per the manufacturer’s proto-
col. Experiments were performed in duplicate. Samples were
analysed using the BD FACSVerse analyser and results sum-
marised using Graphpad Prism.
Results
Patient and disease characteristics for discovery cohort
Ninety-one patients received ipilimumab or anti-PD1
with a pre-treatment FDG PET scan in the study period.
One patient had metabolic tumour volume of zero and
was excluded from all analyses. Of the 90 evaluable pa-
tients: 50 patients received ipilimumab only, 20 patients
received anti-PD1 only and 20 patients received ipilimu-
mab followed by anti-PD1. The cohort of patients is
summarised in Table 1. The median age of patients was
61 years, 67% were men, and 67% had visceral M1c dis-
ease. One patient was excluded from the analyses for
SLR as she had previously undergone a splenectomy.
Pre-treatment FDG PET and patient survival in discovery
cohort
The 90 patients had a median tumoral SUVmax of 16.6
(Range 2.2–78.2, IQR 12.1–23.7), median MTV of 60.2ml
Table 1 Patient clinical and disease characteristics















BRAF other 5 (6%)
RAS 9 (10%)
Other 1 (1%)
No mutation 54 (60%)
Not reported 3 (3%)
Lactate dehydrogenase (n = 78)
< 1xULN 26 (33%)
> 1xULN 52 (67%)




Table 2 Baseline PET parameters of discovery cohort (all
patients treated with immunotherapy, n = 90)
PET parameter Mean Median Range IQR
Tumoral SUV max 20.3 16.6 [2.2, 78.21] 12.12–23.74
SUV mean 6.9 6.1 [1.7, 18.92] 5.33–7.54
MTV (mL) 197.6 60.2 [0.03, 2694] 13.47–212.74
SLR 0.9 0.9 [0.669, 1.364] 0.81–0.97
PET Positron emission tomography; IQR Interquarter range; SUVmax Maximum
Standardised Uptake Value; SUVmean Mean Standardised Uptake Value; MTV
Metabolic Tumour Volume; SLR Spleen to Liver Ratio
Table 3 Baseline PET parameters of discovery cohort (patients
treated with ipilimumab, n = 70)
PET parameter Mean Median Range IQR
Tumoral SUV max 19.3 16.1 [2.2,71.8] [11.6,21.5]
SUV mean 6.8 6.1 [1.7, 18.9] [5.1–7.5]
MTV (mL) 175.2 36.3 [0.03,2693.7] [12.5167.1]
SLR 0.9 0.9 [0.669, 1.364] 0.81–0.97
PET Positron emission tomography; IQR Interquarter range; SUVmax Maximum
Standardised Uptake Value; SUVmean Mean Standardised Uptake Value; MTV
Metabolic Tumour Volume; SLR Spleen to Liver Ratio
Table 4 Baseline PET parameters of discovery cohort (patients
treated with antiPD1, n = 40)
PET parameter Mean Median Range IQR
Tumoral SUV max 20.3 16.6 [2.2, 78.21] 12.12–23.74
SUV mean 6.9 6.1 [1.7, 18.92] 5.33–7.54
MTV (mL) 197.6 60.2 [0.03, 2694] 13.47–212.74
SLR 0.9 0.9 [0.669, 1.364] 0.81–0.97
PET Positron emission tomography; IQR Interquarter range; SUVmax Maximum
Standardised Uptake Value; SUVmean Mean Standardised Uptake Value; MTV
Metabolic Tumour Volume; SLR Spleen to Liver Ratio
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(Range 0.03–2693.7, IQR 13.5–212.7) and median SLR of 0.9
(Range 0.7–1.4, IQR 0.8–1.0) shown in Table 2. The baseline
PET parameters of all evaluable patients in the discovery co-
hort (n = 90) are shown in Table 2. The baseline PET
parameters prior to ipilimumab treatment in the discovery
cohort (n = 70) are shown in Table 3. The baseline PET
parameters prior to anti-PD1in the discovery cohort (n = 40)
are shown in Table 4.
Tumoral SUVmax was not significantly associated with
PFS after ipilimumab or antiPD1 when dichotomized at
the median of the cohort (HR 0.78, p = 0.348 and HR 0.81,
p = 0.560 respectively). See Table 5. Tumoral SUVmax
was also not significantly associated with PFS when ana-
lysed as a continuous variable, HR 1.00 for ipilimumab
with p = 0.74 and HR 0.98 for anti-PD1 with p = 0.23.
MTV was not statistically significant in its association with
PFS when dichotomized at the median of the cohort for
ipilimumab (MTV > 41ml, HR 1.45 with p = 0.23) or for
anti-PD1 (MTV > 140ml, HR 0.94 with p = 0.86). MTV
was also not significantly associated with PFS when ana-
lysed as a continuous variable, HR 1.07 for ipilimumab
with p = 0.07; and HR = 1.00 for anti-PD1 with p = 0.86.
However, strikingly, high SLR > 1.1 was associated with
poor PFS after ipilimumab compared to patients with nor-
mal SLR (median PFS 1.0 vs 3.0 months, HR 3.14, p =
0.008), but was not associated with PFS after anti-PD1
(median 3.0 vs 3.0 months, HR 0.56, p = 0.324).
Overall survival was calculated from date of first treat-
ment separately for each agent, as well as for date of first
line immunotherapy. High SLR was also associated with
short OS as calculated from start of first line immunother-
apy (median 1.0month vs 14.0months respectively, HR
3.92, p = 0.003). See Table 6 and Fig. 2c. Patients with high
SLR > 1.1 also had significantly worse OS compared to pa-
tients with normal SLR after ipilimumab (median 1 vs 21
months; HR 5.83, p = 0.0001). See Fig. 2d. High SLR was
not associated with OS after anti-PD1 treatment (median
8.8 v 9.7 months; HR 0.92, p = 0.89).
Again, high tumoral SUVmax was not associated with
OS after first line immunotherapy compared to low tu-
moral SUVmax, (median OS 14.0 vs 9.0 months, HR
0.57, p = 0.053). High tumoral SUVmax was not associ-
ated with OS after ipilimumab (HR 0.83, p = 0.59) or
after anti-PD1 (HR 0.57, p = 0.267). SUVmax also not
significantly associated with OS after first line immuno-
therapy when analysed as a continuous variable, HR 0.99
with p = 0.21.
Interestingly, high MTV were not associated with OS
after first line immunotherapy compared to patients with
low MTV when dichotomised at the median (median
OS 9.0 vs 20.0 months, HR 1.18, p = 0.606) but MTV
was significantly associated with OS when analysed as a
continuous variable (HR 1.09, p = 0.020). Similarly, high
MTV was not associated with OS after ipilimumab (HR
1.08, p = 0.827) or after anti-PD1 (HR 1.67, p = 0.294).
We explored this further by splitting the cohort into
MTV quintiles and found that the quintile with the low-
est level of disease had excellent OS whereas the
remaining 4 quintiles all appeared to have similar OS.
This suggests a degree of non-linearity between the
MTV and OS with excellent survival in patients with
very low volume of disease as shown in Fig. 3.
Multivariable analysis for progression free survival and
overall survival in discovery cohort
On multivariable analysis, SLR was independently asso-
ciated with survival, with HR 3.58 (95% CI 1.34–9.61), p
0.0026. The other variables including LDH, metastasis
substage, MTV, absolute lymphocyte count (ALC) were
all non-significant. See Tables 7 and 8.
For PFS analysis, multivariable analysis was performed
only for the ipilimumab-treated cohort of patients, as
Table 5 Association between PET parameters and progression free survival, for ipilimumab and anti-PD1 treatment, analysed as
continuous variable and dichotomized at the median for the cohort
Ipilimumab (n = 70) Anti-PD1 (n = 40)
PET
parameter
Level n HR HR 95% CI P-value Level n HR HR 95% CI P-value
Tumoral SUVmax 0.997 [0.978, 1.02] 0.74 0.984 [0.958, 1.01] 0.23
MTV (mL) 1.07 [1.01, 1.14] 0.066 0.993 [0.924, 1.07] 0.86
SLR 8.24 [1.08, 63.1] 0.05 0.904 [0.0623, 13.1] 0.94
Tumoral SUVmax ≤18 39 1 – 0.348 ≤18 16 1 – 0.56
> 18 31 0.78 [0.46, 1.31] > 18 24 0.81 [0.39, 1.66]
MTV (mL) ≤41 34 1 – 0.231 ≤140 20 1 – 0.86
> 41 36 1.45 [0.79, 2.68] > 140 20 0.94 [0.46, 1.90]
SLR ≤1.1 60 1 – 0.008 ≤1.1 35 1 – 0.32
> 1.1 9 3.14 [1.46, 6.75] > 1.1 5 0.56 [0.16, 1.92]
Anti-PD1 Anti-programmed death 1 monoclonal antibody; PET Positron emission tomography; HR Hazard ratio; CI Confidence interval; SUVmax Maximum
Standardised Uptake Value; SUVmean Mean Standardised Uptake Value; MTV Metabolic Tumour Volume
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the univariable regressions for anti-PD1 all resulted in
non-statistically significant p-values (> 0.05). For PFS
after ipilimumab, SLR was associated with HR 2.67 (95%
CI 1.13–6.33), p = 0.042.
Validation cohort
One hundred ten patients treated with ipilimumab be-
tween May 2007 and April 2015 were included. Fifty-
eight patients were from UZ Brussel, Brussels and 52
patients were from University Hospital Zurich, Zurich.
Patient and disease characteristics are described in Sup-
plementary materials (S4). There were higher propor-
tions of patients with M1c in the Brussels cohort, but
this difference was negligible when the patients were
combined into a single validation cohort (68% of the dis-
covery cohort had M1c disease compared to 73% of the
validation cohort). The proportion of patients with the
high SLR was also lower in the European cohort com-
pared to Australian patients (4% compared to 13%). Des-
pite these differences, SLR > 1.1 was still associated with
poor OS after ipilimumab (median 2.3 months versus
11.9 months, HR 3.74, CI 1.34–10.4), as shown in Fig. 4.
Biological analyses for discovery cohort
We sought to explore the cause of the raised SLR. We
compared the PET parameters of liver and splenic SUV
in patients with raised SLR and normal SLR. In patients
with raised SLR, the mean and median liver SUV was
2.0 with an interquartile range (IQR) of 0.5, which is
slightly lower than the normal reference range (lower
limit of normal for liver SUV was 2.3) [20]. In contrast,
the normal SLR group had a mean and median liver
SUV of 2.4, IQR 0.6; which is within the normal refer-
ence range. Within the high SLR group, the mean and
median splenic SUV was 2.4, with IQR of 0.4; whereas in
normal SLR group, where the mean and median splenic
SUV was 2.1, IQR 0.5.
To explore the relationship of SLR and inflammatory
or haematological parameters, a multivariable linear re-
gression model for SLR was considered, considering:
Neutrophil: Lymphocyte Ratio, Absolute Neutrophil
Count (< 7.5 vs. ≥7.5), Haemoglobin (< 120 vs. ≥120),
LDH (≤ULN vs. >ULN), ALC × 109 (< 1 vs. ≥1), albumin
(< 35 vs. ≥35), Lymphocyte: Monocyte ratio and patient
performance status. Only albumin was found to be sig-
nificantly associated with SLR, beta − 0.15 (CI -0.209, −
0.091, p < 0.001). See supplementary materials S2. Given
that albumin is a negative acute phase marker (i.e. de-
crease during inflammation), the inflammatory cytokine
profile was examined in patients with stored sera.
Fourteen patients in the discovery cohort had evalu-
able stored sera from baseline, week 3 and week 6 post
commencement of ipilimumab. Of these patients, 13 had
normal SLR, whereas one patient had high SLR > 1.1.
There were no major differences in the baseline levels
nor the dynamic changes in IL2, IL1 beta, IL4, IL6, IL10,
IL17, IL12p70, IFN gamma and TNF alpha post ipilimu-
mab, when comparing the patient with high SLR to
others with normal SLR. Patients with progressive dis-
ease and high SLR were both observed to have a loga-
rithmic increase in IL6 and IL10 at week 3 and week 6.
See supplementary materials S3.
Table 6 Association between PET imaging parameters and
overall survival, analysed as continuous variable and
dichotomized at the median for the cohort
Ipilimumab (n = 70)
PET parameter Level n HR HR 95% CI P-value
Tumoral SUVmax 0.983 [0.95,1.01] 0.24
MTV 1.000 [1.00, 1.001] 0.03
SLR 18.71 [1.34, 261.25] 0.02
Tumoral SUVmax < 16.07 35 1 –
> 16.07 35 0.83 [0.42, 1.63] 0.59
MTV (mL) < 41.38 35 1 –
> 41.38 35 1.09 [0.52, 2.29] 0.83
SLR < 1.1 59 1 –
> 1.1 10 5.83 [2.31–14.74] 0.0002
Anti-PD1 (n = 40)
PET parameter Level n HR HR 95% CI P-value
Tumoral SUVmax 0.967 [0.93, 1.007] 0.10
MTV 1.000 [0.9995, 1.001] 0.49
SLR 2.419 [0.08, 76.00] 0.62
Tumoral SUVmax < 19.33 20 1 –
> 19.33 20 0.57 [0.21, 1.53] 0.27
MTV (mL) < 137 20 1 –
> 137 20 1.67 [0.64, 4.34] 0.29
SLR < 1.1 35 1 –
> 1.1 5 0.92 [0.26, 3.29] 0.89
First line immunotherapy (n = 90)
PET parameter Level n HR HR 95% CI P-value
Tumoral SUVmax 0.986 [0.964, 1.01] 0.21
MTV 1.09 [1.02, 1.15] 0.02
SLR 17.3 [1.90, 157] 0.02
Tumoral SUVmax ≤18 49 1 – 0.05
> 18 41 0.57 [0.32, 1.01]
MTV (mL) ≤76 51 1 – 0.61
> 76 39 1.18 [0.63, 2.23]
SLR ≤1.1 79 1 – 0.003
> 1.1 10 3.92 [1.76, 8.72]
PET Positron emission tomography; SUVmax Maximum Standardised Uptake
Value; MTV Metabolic Tumour Volume; SLR Spleen to Liver Ratio
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Fig. 2 (See legend on next page.)
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Discussion
High SLR on pre-treatment FDG-PET was associated
with poor OS after ipilimumab for advanced melanoma
in our study. This finding was then validated in an add-
itional combined cohort of patients from two separate
institutions. Although only a small proportion of pa-
tients exhibited high SLR (i.e. only 10% of the discovery
cohort and 4% of the validation cohort), it is noteworthy
that these patients had a very poor prognosis after ipili-
mumab (OS 1–3 months compared to 10–15 months in
phase III studies) [1, 29, 30]. In the discovery cohort,
high SLR was associated with poor PFS after ipilimumab
but not after anti-PD1. This may be due to the small
sample size of the anti-PD1 cohort or it may be due to
the different mechanisms of action between the two
treatments.
(See figure on previous page.)
Fig. 2 a. Kaplan Meier curves of FDG PET parameters and Progression free survival after ipilimumab. b. Kaplan Meier curves of FDG-PET
parameters and Progression free survival after anti-PD1. c. Kaplan Meier curves of FDG-PET parameters and overall survival from the start of first
line immunotherapy. d. Kaplan Meier curves of Spleen to Liver Ratio (SLR) and overall survival after ipilimumab and anti-PD1 respectively. (A) and
(B). Kaplan Meier survival curves for progression free survival after ipilimumab or anti-PD1 and its correlation for SUVmax, Metabolic Tumour
Volume (MTV) and spleen to liver ratio (SLR) respectively. High SLR was significantly correlated with PFS after ipilimumab (median PFS 1.0 vs 3.0
months, HR 3.14, p = 0.008), but was not associated with PFS after anti-PD1 (median 3.0 vs 3.0 months, HR 0.56, p = 0.324). Figure 2(c) High SLR
was associated with poor OS after first line immunotherapy (ipilimumab or anti-PD1), median 1 vs 14months; HR 3.92, p = 0.003. Neither SUVmax
nor MTV was significantly associated with PFS or OS after either treatment. Figure 2(D) High SLR was associated with poor OS after ipilimumab
(median 1 v 21months, HR 5.83, p = 0.0001. High SLR was not associated with OS after anti-PD1 treatment (median 8.8 v 9.7 months; HR
0.92, p = 0.89)
Fig. 3 Overall survival curves stratified by metabolic tumour volume quintile. High metabolic tumour volume (MTV) was not associated with OS
compared to patients with low MTV when dichotomised at the median (HR 1.18, p = 0.606) but MTV was significantly associated with OS when
analysed as a continuous variable (HR 1.09, p = 0.020). To explore this further, the discovery cohort was split into MTV quintiles and found that the
quintile with the lowest level of disease had excellent OS whereas the remaining 4 quintiles all appeared to have similar OS. This suggests a
degree of non-linearity between the MTV and OS
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Caution is advised when interpreting the overall sur-
vival analyses for each immunotherapy separately. Pa-
tients in this study was treated during a transitional
period where ipilimumab was the standard first line im-
munotherapy at the start of the study period (n = 50).
Patients who received first line ipilimumab were able to
receive anti-PD1 upon disease progression (n = 20). To-
wards the end of the study period, patients were able to
receive anti-PD1 as their first line therapy (n = 20). The
overall survival analysis of a cancer treatment could be
influenced by subsequent treatments. In the case of im-
munotherapy, there is also the potential that overall sur-
vival is influenced by prior treatments given the long
half-life of these agents and possible changes to the pa-
tients’ immune system following first line treatment. We
attempted to address this in the study by analysing the
overall survival from the start of the first line immuno-
therapy treatment so that patients contributed only once
to survival censoring (n = 70). Using this analysis
method, high SLR remained associated with poor OS
after first line immunotherapy.
The mechanism for high splenic avidity is not well
understood. The spleen, being the largest lymphoid
organ in the human body, is the site of immune cell acti-
vation and maturation. Increased splenic avidity on
FDG-PET has been previously reported in lymphoma,
granulomatous diseases, GCSF injections and interferon-
alpha administration in melanoma [31]. Pak and
colleagues have also studied this phenomenon more ex-
tensively in the context of cholangiocarcinoma [21].
They showed that high splenic avidity is associated with
poor survival in patients with metastatic cholangiocarci-
noma [22]. However, this signature has not been studied
prior to immune modulation with ipilimumab or anti-
PD1 in the setting of advanced melanoma.
Pak et al. demonstrated that high SLR in patients with
cholangiocarcinoma is associated with markers of in-
flammation including leucocytosis, raised CRP, raised
levels of IL-1b, IL-1RA, IL-4, IL-6, IL-7 and IL-13 [21].
These inflammatory cytokines are suggestive of an acute
phase inflammatory response or activation of humoral
immunity. In our cohort, we found that patients with
high SLR post ipilimumab were more likely to have low
albumin, but importantly independent of leucocytosis or
high neutrophil: lymphocyte ratio. Our cohort of 14 pa-
tients with stored sera was too small to perform com-
parative statistics but we did not find any striking
differences in the cytokine profile of the patient with
high SLR. It would be of interest to explore in future
studies whether this splenic avidity is a result of systemic
cytokines or preferential glucose metabolism in specific
immune cells within the spleen. We postulate that the
failure to control disease despite already invoking im-
mune activation may underlie the lack of benefit from
further stimulation by immunotherapy.
Additionally, the abnormal SLR group was associated
with decreased hepatic uptake as well as increased
splenic uptake. This raises the possibility that SLR could
be related to both reduced liver SUV as well as high
splenic SUV rather than either factor alone. However,
our study only included a small number of patients with
raised SLR signature so it would be important to explore
this in larger cohorts.
No evidence of association between high tumoral
SUVmax and outcome after immunotherapy was found.
This may be because tumoral glucose uptake is not only
due to malignant cells, but also is caused by immune
cells as part of immune activation. Therefore, examin-
ation of tumoral SUVmax alone may be problematic in
the context of immunotherapy and diseases in which im-
mune modulation is important for disease outcomes.
MTV was not associated with PFS in either ipilimumab
or anti-PD1 in our cohort but was significantly
Table 7 Multivariate analysis for progression free survival after
ipilimumab
Predictor Level HR HR 95% CI P-value
LDH ≤ULN 1 – 0.738
>ULN 1.12 [0.58, 2.14]
Stage not M1c 1 – 0.431
M1c 1.32 [0.66, 2.67]
MTV ≤41 1 – 0.334
> 41 1.39 [0.71, 2.70]
ALC ≤1 1 – 0.083
> 1 0.55 [0.28, 1.06]
SLR ≤1.1 1 – 0.042
> 1.1 2.67 [1.13, 6.33]
LDH Lactate dehydrogenase; ULN Upper limit of normal; MTV Metabolic
Tumour Volume; ALC Absolute Lymphocyte Count; SLR Spleen to Liver Ratio
Table 8 Multivariate analysis for overall survival after first line
immunotherapy
Predictor Level HR HR 95% CI P-value
LDH ≤ULN 1 – 0.076
>ULN 2.13 [0.89, 5.08]
Stage not M1c 1 – 0.163
M1c 1.88 [0.75, 4.75]
MTV ≤76 1 – 0.973
> 76 1.01 [0.51, 2.02]
ALC ≤1 1 – 0.164
> 1 0.61 [0.30, 1.21]
SLR ≤1.1 1 – 0.026
> 1.1 3.58 [1.34, 9.61]
LDH Lactate dehydrogenase; ULN Upper limit of normal; MTV Metabolic
Tumour Volume; ALC Absolute Lymphocyte Count; SLR Spleen to Liver Ratio
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associated with OS when analysed as a continuous vari-
able. The patient group with very low levels of tumour
volume appeared to have very good survival whereas the
relationship did not appear linear at larger tumour vol-
umes, this finding needs to be taken with caution given
it has not been externally validated. However, it does ap-
pear to be in keeping with the findings of other investi-
gators who have also correlated anti-PD1 response with
tumoral burden as measured by CT [32, 33]. Our cohort
predominantly evaluated patients treated with ipilimu-
mab, and only included 40 patients treated with anti-
PD1. It may be that MTV is of higher predictive value
for anti-PD1 alone and should be evaluated in a larger
cohort to better understand an optimal threshold for
analysis, and its utility for that treatment.
From a technical standpoint, SLR may be an easier
parameter to apply clinically than absolute thresholds of
significance for parameters such as tumoral SUV or
MTV. Despite effort to harmonise its measurement [16],
tumoral SUVmax can be a more challenging parameter
to reproduce in multi-centre studies, owing to the need
for the same imaging systems, acquisition parameters,
reconstruction parameters, and tracer uptake times in
order to obtain an accurate and reproducible measure-
ment of SUVmax. In the case of the SLR, the precise
measure of SUV is less important. Examination of the
same patient on multiple scanners, may produce differ-
ent SUV but the ratio will remain the same. Conse-
quently, this makes SLR a more robust measure for
comparison between different study sites.
Our study does shift the focus of functional imaging of
the tumour alone to the role of functional imaging of the
host immune system. This additional use of PET scans
gives a snapshot of the host immune status and may com-
plement other biomarkers as suggested by Blank et al.
[11]. Further understanding of the biological significance
of avidity and activation of splenic avidity or draining lym-
phatics of the tumour may improve the understanding of
not only the mechanism of action of immunotherapies,
but also possible targets for future research into specific
body sites contributing to treatment resistance.
Our study was limited by its retrospective nature, its
relatively small sample size and lack of homogenous as-
sessment modalities for PFS. Our findings were validated
in an independent cohort albeit only in a small number
of patients exhibited high SLR. The combined validation
cohort had a similar proportion of patients with M1c
disease but there was variation in the prior treatments
received. Despite the low occurrence of high SLR, this
parameter was associated with very poor clinical
Fig. 4 SLR and overall survival after ipilimumab in the validation cohort. High SLR was associated with poor overall survival after ipilimumab
treatment. This was validated in an external cohort (n = 110 patients) from Brussels and Zurich (median 2.3 months versus 11.9 months, HR 3.74,
CI 1.34–10.4)
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outcome and may be useful in identifying patients who
should not receive ipilimumab treatment. This param-
eter also needs to be prospectively assessed in larger co-
horts of patients treated with second line ipilimumab or
ipilimumab combinations (ipilimumab/nivolumab).
Conclusion
Pre-treatment high SLR on FDG PET/CT was associated
with poor outcome after ipilimumab in advanced melan-
oma. Further prospective validation of this FDG PET/
CT signature is required, particularly in larger cohorts of
patients treated with anti-PD1 or ipilimumab combin-
ation therapies.
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